MEDSIR
MEDSIR is a Barcelona-based oncology clinical research organization founded in 2012 that designs and manages investigator-initiated clinical trials for pharmaceutical and biotech sponsors across 14+ countries, working with 600+ investigators and 40+ industry partners.
- Company typePrivate
- Founded2012
- HeadquartersBarcelona, Spain
- Headcount51–100
- GTM typeB2B
- OfferingServices
What MEDSIR does
MEDSIR (Medica Scientia Innovation Research, SL) is a Barcelona-headquartered, privately held clinical research organization founded in 2012 by breast cancer oncologists Javier Cortés, Antonio Llombart, and CEO Maria Campos. The company designs and manages investigator-initiated and strategic clinical trials in oncology, with a portfolio of more than 65 trials spanning breast, lung, prostate, penile, and thymic cancers, executed across 196+ trial sites in 14+ countries with a network of 615+ research collaborators. Its core deliverables include study conception, protocol design, trial management, regulatory support, and publication of results, and it operates a Spanish-language patient information portal (Convive con el Cancer).
Revenue is generated primarily through professional services fees paid by pharmaceutical and biotech sponsors for clinical trial execution, supplemented by collaborative programs in which industry partners provide drug supply (e.g., Pfizer, AstraZeneca, Astellas, Menarini/Stemline, Roche, Karyopharm) and funding. MEDSIR also receives drug supply and strategic alignment from diagnostics and platform players such as Natera and Ataraxis AI. The commercial model is relationship-driven, anchored on long-standing key opinion leader relationships and active participation in oncology congresses (ASCO, ESMO, SABCS). The company is independently owned with no disclosed external venture or private equity funding and operates from Barcelona and Boston.
Operationally, MEDSIR holds ISO 9001 (quality) and ISO 27001 (information security) certifications and reports 146 scientific outputs (52 peer-reviewed manuscripts and 94 congress presentations), with 67% of publications appearing in Q1 journals including The Lancet, Nature, and the Journal of Clinical Oncology. Its go-to-market is hybrid: enterprise sales to pharma/biotech and event-driven scientific engagement with clinical investigators worldwide.
MEDSIR firmographics
Firmographics- Name
- MEDSIR
- Legal name
- Medica Scientia Innovation Research, SL
- Website
- https://medsir.org
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- MEDSIR is a Barcelona-based oncology clinical research organization founded in 2012 that designs and manages investigator-initiated clinical trials for pharmaceutical and biotech sponsors across 14+ countries, working with 600+ investigators and 40+ industry partners.
- Ownership category
- akta.pro rank
Where MEDSIR is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
MEDSIR business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Trial Management Services: MEDSIR provides end-to-end clinical trial services including study conception, design, management, and publication of results. Revenue is generated through fees charged to pharmaceutical companies and biotech partners for clinical trial sponsorship, protocol development, site management, and regulatory support.
- Strategic Partnership Services: MEDSIR collaborates with pharmaceutical companies on investigator-initiated trials, receiving funding and drug supply from industry partners while providing clinical research expertise and access to global investigator networks.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
MEDSIR product offering
Product offeringCore offering
MEDSIR designs and manages strategic clinical trials in oncology from study conception through publication of results. The company operates a collaborative research model that connects expert clinical investigators and key opinion leaders with pharmaceutical companies and biotech innovators to develop innovative oncology trials. Services include protocol design, site management, regulatory support, operational execution, and publication support across a portfolio of investigator-initiated and industry-sponsored studies.
Product overview
MEDSIR (Medica Scientia Innovation Research) is an international oncology clinical research organization that designs and manages strategic clinical trials in oncology, from study conception to publication of results. The company operates a portfolio of clinical trials including PHERGain, PHERGain-2, PARSIFAL, ORPHEUS, SLLIP, MiRaDoR, DEMETHER, PHENOMENAL, TUXEDO-4, ADELA, CADILLAC, ZZ-FIRST, EMPRESS, and PECATI across various cancer types (breast, lung, prostate, penile, thymic). Additionally, MEDSIR offers the Convive con el Cancer patient portal and provides strategic services for clinical trial design, operational strategy, and investigator support. The company collaborates with pharmaceutical partners including Menarini Group, Roche, Pfizer, AstraZeneca, and others to conduct investigator-initiated trials and industry-sponsored studies.
Differentiator
Problem solved
Functional benefit
Products and services
- Strategic Services
Quantifiable outcome
- Nearly 90% disease-free survival five years post-surgery in PHERGain study
- +4 more outcomes
Companies that use MEDSIR
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles1 record
MEDSIR technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
MEDSIR partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- Menarini Group (Stemline Therapeutics)coreMEDSIR collaboration with Menarini Group on multiple clinical trials including ADELA (phase III evaluating elacestrant plus everolimus) and ELECTRA studies. Menarini and Stemline Therapeutics present data at ASCO 2026 on elacestrant across solid tumors and hematologic malignancies.
- Astellas Pharma EuropeminorAstellas provides enzalutamide for the ZZ-FIRST study evaluating therapeutic intensification in metastatic hormone-sensitive prostate cancer.
- Karyopharm TherapeuticsminorPartner Karyopharm Therapeutics presented late-breaking oral results from the phase 3 SENTRY trial of selinexor in myelofibrosis patients at ASCO 2026.
- NateracoreMEDSIR and Natera announced collaboration on the MiRaDoR phase II clinical trial in breast cancer, evaluating treatment approaches for HR+/HER2- patients using Natera's Signatera Genome ctDNA test. The trial involves up to 60 Signatera-positive patients across multiple treatment arms to assess treatment response through circulating tumor DNA levels.
- PfizercorePfizer provides talazoparib (PARP inhibitor) for the ZZ-FIRST study evaluating enzalutamide plus talazoparib in metastatic hormone-sensitive prostate cancer. Also provided palbociclib for PARSIFAL study.
- AstraZenecaminorAstraZeneca provided fulvestrant for the PARSIFAL study comparing palbociclib combinations in metastatic breast cancer.
- Oncoclínicas & CocoreStrategic alliance with Oncoclínicas, the leading oncology group in Latin America, to scale independent clinical research across continents. MEDSIR is part of Oncoclínicas group, which operates 145 units across 39 Brazilian cities and is the exclusive partner in Brazil of Dana Farber Cancer Institute.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
MEDSIR competitors and assessment
Company assessmentDirect peers
- Theradex Oncology CRO: Specialized oncology CRO providing clinical operations, data management, and monitoring for cancer trials globally; a close analog to MEDSIR's pure-play oncology positioning.
- Medpace Holdings: Mid-to-large global CRO with a strong and growing oncology franchise serving biotech and pharma sponsors on Phase I–III trials; competes for the same investigator-initiated and sponsor-led oncology work as MEDSIR.
- Worldwide Clinical Trials: Mid-sized global CRO with deep oncology and rare disease expertise; competes with MEDSIR for biotech and pharma-sponsored oncology trials across Phase II–III.
- Sarah Cannon Research Institute: Oncology-focused clinical research network operating Phase I and late-phase community-based trials in the US; comparable to MEDSIR in its site-network approach and pharma partnership model.
- EORTC: European Organisation for Research and Treatment of Cancer — academic research organization running oncology trials across European sites; matches MEDSIR's pan-European, oncology-only, KOL-driven operating model.
- Breast International Group (BIG): Academic research organization coordinating large-scale breast cancer clinical trials across global networks; closest non-commercial analog to MEDSIR's investigator-network, IIT-driven model in breast oncology.
Broad incumbents
- ICON plc: One of the largest global CROs with a broad therapeutic portfolio including oncology; a higher-overhead, full-service incumbent that competes for the same pharma-sponsored oncology trials.
- Parexel International: Established global CRO with significant oncology and biotech customer base; competes for full-service oncology trial execution mandates similar to those MEDSIR pursues.
- Syneos Health: Large biopharma solutions organization combining CRO and commercial services; competes for outsourced oncology development programs from biotech and pharma sponsors.
- IQVIA: Largest global CRO and life-science services franchise with extensive oncology operations; competitors with MEDSIR for Big Pharma outsourcing contracts across all phases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
MEDSIR social profiles
Digital presenceMEDSIR compliance and trust
Trust signalCompliance2 records
MEDSIR financial estimates
Financial estimateRevenue estimate
Valuation estimate
MEDSIR leadership team
Management profileNumber of profiles
Profiles8 records
MEDSIR funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MEDSIR M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MEDSIR
What does MEDSIR do?
MEDSIR designs and manages strategic clinical trials in oncology from study conception through publication of results. The company operates a collaborative research model that connects expert clinical investigators and key opinion leaders with pharmaceutical companies and biotech innovators to develop innovative oncology trials. Services include protocol design, site management, regulatory support, operational execution, and publication support across a portfolio of investigator-initiated and industry-sponsored studies.
Is MEDSIR a public or private company?
MEDSIR is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MEDSIR founded?
MEDSIR was founded in 2012. It employs 51 to 100 people.
Where is MEDSIR based?
MEDSIR is headquartered in Barcelona, Spain, in the Europe region.
How does MEDSIR make money?
Two revenue lines are on record. Clinical Trial Management Services are the primary driver. The others are strategic Partnership Services.
Who are MEDSIR's main competitors?
Direct peers on record are Theradex Oncology CRO, Medpace Holdings, Worldwide Clinical Trials, Sarah Cannon Research Institute, EORTC and Breast International Group (BIG). Broad incumbents are ICON plc, Parexel International, Syneos Health and IQVIA.
Does MEDSIR have an API?
No public API is recorded for MEDSIR.